Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy
Summary
Adjunctive azetukalner cut monthly focal onset seizure frequency by 53% in phase III study
Description
Adjunctive azetukalner cut monthly focal onset seizure frequency by 53% in phase III study
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source